Forkhead box O3
Forkhead box O3
Overview
Forkhead box O3 (FOXO3, also referred to in some contexts as FOXO3a) is a member of the FOXO subfamily of forkhead transcription factors. As a protein-coding regulatory factor, it helps control gene expression programs involved in cellular stress responses, antioxidant defense, metabolism, and survival. In biomedical research, FOXO3 is frequently studied as a downstream effector of signaling pathways such as AKT, AMPK, and SIRT1, where its activity can be modulated by phosphorylation or acetylation to alter transcriptional output.
Functionally, FOXO3 is notable for its role in oxidative stress regulation. Recent studies have linked FOXO3 activity to the transcriptional upregulation of antioxidant genes including SOD2, HO-1, and CAT, and to broader pathways involving ferroptosis, chronic mountain sickness, photoaging, and musculoskeletal phenotypes. Because of these roles, FOXO3 is of interest both as a mechanistic node in disease biology and as a potential therapeutic target in conditions where redox balance, energy metabolism, or tissue degeneration are disrupted.
Focus of Latest Publications
Recent publications have examined Forkhead box O3 (FOXO3) as a signaling node in diverse stress-response and aging-related contexts, particularly in muscle, skin, nervous system, and pregnancy biology. In advanced maternal age pregnancies, low FOXO3 expression in decidual macrophages was reported to contribute to macrophage senescence by downregulating mitophagy, alongside increased proinflammatory M1 polarization, elevated tumor protein p53 and SA-β-Gal, and reduced phagocytic capacity. The same study also implicated elevated IL-6 in the uterine microenvironment as an additional driver of senescence, and showed that adoptive transfer of young bone marrow-derived macrophages improved embryo resorption rates and placental development in aged pregnant mice.
FOXO3 has also been linked to oxidative stress and tissue aging. In human dermal fibroblasts exposed to repetitive UVA irradiation, SIRT1 activation with SRT1720 reduced oxidative stress, DNA damage, cellular senescence, and extracellular matrix degradation. Mechanistically, SIRT1 deacetylated and stabilized FOXO3a, which then upregulated antioxidant defense genes including SOD2, HO-1, and CAT; FOXO3 knockdown abolished the protective effects, identifying FOXO3 as the essential downstream effector in this anti-photoaging response. In another study of chronic mountain sickness, Bawei Chenxiang Wan was investigated as a treatment targeting the AKT/FOXO3a/CAT axis to inhibit oxidative stress.
In skeletal muscle, FOXO3 was repeatedly associated with atrophy-related proteolysis. Phillyrin attenuated dexamethasone-induced muscle atrophy in mice and was reported to inhibit FOXO3a-mediated proteolysis, alongside restoration of intramuscular prostaglandin E2, EP4 signaling, and partial recovery of mTOR and PGC-1α signaling. Separately, compounds identified by screening as inhibitors of FOXO1/3a activity suppressed dexamethasone-induced Atrogin1 expression in C2C12 myoblasts, suggesting that blocking FOXO1/3a can reduce atrophy-associated gene induction. FOXO3 was also highlighted in a genomic study of osteosarcopenia, where TWAS and MAGMA converged on FOXO3 as a dual susceptibility gene across bone and muscle phenotypes.
Additional studies connected FOXO3a to metabolic and neuronal stress pathways. In epileptic rats, inhibition of aerobic glycolysis was investigated for its ability to suppress ferroptosis through activation of the AMPK-FoxO3a signaling pathway. Together, these publications position FOXO3 as a regulator of senescence, antioxidant defense, proteolysis, and ferroptosis-related injury, with therapeutic modulation explored through SIRT1 activation, natural compounds, traditional medicine, and pathway-targeted interventions.